| Dr David Harlan Aizuss, MD | |
|
16311 Ventura Blvd, 750, Encino, CA 91436-2124 | |
| (818) 990-3623 | |
| Not Available |
| Full Name | Dr David Harlan Aizuss |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 44 Years |
| Location | 16311 Ventura Blvd, Encino, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346221728 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | G44840 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ophthalmology Associates Of The Valley Medical Group | 9032001342 | 9 |
News Archive
TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced presentations of new data on its Smac mimetic drug candidate TL32711 at the 2011 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics in San Francisco.
Among patients with end-stage renal disease undergoing living-related kidney transplants, the use of bone-marrow derived mesenchymal (cells that can differentiate into a variety of cell types) stem cells instead of antibody induction therapy resulted in a lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated kidney function at 1 year, according to a study in the March 21 issue of JAMA.
Novian Health, developer of Novilase® Breast Therapy, announced that the US Food and Drug Administration (FDA) has granted investigational device exemption (IDE) approval for the company to start a multi-center study of its Novilase® Interstitial Laser Therapy (ILT) System. Novian developed the ILT System for the ablation of small (up to 20 mm) malignant breast tumors.
Cardinal Health today announced the early renewal of its distribution agreement with Walgreens to supply pharmaceuticals to its national network of retail pharmacies. The new agreement extends into 2013.
It's a new day for health insurance companies. As the Affordable Care Act forces an industry shift towards consumerism, individuals are becoming more involved in their own health care decisions and insurers are becoming more involved in their members' lives.
› Verified 6 days ago
| Entity Name | Ophthalmology Associates Of The Valley Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962483537 PECOS PAC ID: 9032001342 Enrollment ID: O20040329001739 |
News Archive
TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced presentations of new data on its Smac mimetic drug candidate TL32711 at the 2011 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics in San Francisco.
Among patients with end-stage renal disease undergoing living-related kidney transplants, the use of bone-marrow derived mesenchymal (cells that can differentiate into a variety of cell types) stem cells instead of antibody induction therapy resulted in a lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated kidney function at 1 year, according to a study in the March 21 issue of JAMA.
Novian Health, developer of Novilase® Breast Therapy, announced that the US Food and Drug Administration (FDA) has granted investigational device exemption (IDE) approval for the company to start a multi-center study of its Novilase® Interstitial Laser Therapy (ILT) System. Novian developed the ILT System for the ablation of small (up to 20 mm) malignant breast tumors.
Cardinal Health today announced the early renewal of its distribution agreement with Walgreens to supply pharmaceuticals to its national network of retail pharmacies. The new agreement extends into 2013.
It's a new day for health insurance companies. As the Affordable Care Act forces an industry shift towards consumerism, individuals are becoming more involved in their own health care decisions and insurers are becoming more involved in their members' lives.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Harlan Aizuss, MD 16311 Ventura Blvd, 750, Encino, CA 91436-2124 Ph: (818) 990-3623 | Dr David Harlan Aizuss, MD 16311 Ventura Blvd, 750, Encino, CA 91436-2124 Ph: (818) 990-3623 |
News Archive
TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced presentations of new data on its Smac mimetic drug candidate TL32711 at the 2011 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics in San Francisco.
Among patients with end-stage renal disease undergoing living-related kidney transplants, the use of bone-marrow derived mesenchymal (cells that can differentiate into a variety of cell types) stem cells instead of antibody induction therapy resulted in a lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated kidney function at 1 year, according to a study in the March 21 issue of JAMA.
Novian Health, developer of Novilase® Breast Therapy, announced that the US Food and Drug Administration (FDA) has granted investigational device exemption (IDE) approval for the company to start a multi-center study of its Novilase® Interstitial Laser Therapy (ILT) System. Novian developed the ILT System for the ablation of small (up to 20 mm) malignant breast tumors.
Cardinal Health today announced the early renewal of its distribution agreement with Walgreens to supply pharmaceuticals to its national network of retail pharmacies. The new agreement extends into 2013.
It's a new day for health insurance companies. As the Affordable Care Act forces an industry shift towards consumerism, individuals are becoming more involved in their own health care decisions and insurers are becoming more involved in their members' lives.
› Verified 6 days ago
Nicole Koulisis, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 5400 Balboa Blvd Ste 126, Encino, CA 91316 Phone: 818-578-0004 Fax: 818-578-0002 | |
Hajir Dadgostar, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 16500 Ventura Blvd, Suite 250, Encino, CA 91436 Phone: 818-788-9333 Fax: 818-788-9273 | |
Dr. Mark H Kramar, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 16311 Ventura Blvd, Suite #750, Encino, CA 91436 Phone: 818-990-3623 Fax: 818-788-1056 | |
John G Rezapour, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 16661 Ventura Blvd Ste 211, Encino, CA 91436 Phone: 818-205-1200 Fax: 818-205-1254 | |
Dr. Stanley M Kopelow, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 16311 Ventura Blvd, Suite 750, Encino, CA 91436 Phone: 818-990-3623 Fax: 818-788-1056 | |
Dr. Mohammad Reza Kalantari Nejad, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 16661 Ventura Blvd, Suite 312, Encino, CA 91436 Phone: 818-380-9191 Fax: 818-380-9190 | |
Sheryl M Handler, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 16311 Ventura Blvd, Suite 980, Encino, CA 91436 Phone: 818-789-2226 Fax: 818-789-2353 |